receptor associated protein

selected from the group consisting of RAP, a RAP mutant, a RAP analogue and the combination of tissue type plasminogen activator (tPA) and aprotinin.

2. (amended) A preparation according to claim 1, characterized in that said pro-protein is derived from a biological material selected from the group consisting of human plasma, a plasma fraction and a cell culture supernatant.

Q1 cont

3. (amended) A preparation according to claim 1, characterized in that it is provided as a set comprising

a) said pro-protein of blood coagulation and

b) said receptor binding competitor.

4. (amended) A preparation according to claim 1, characterized in that said pro-protein of blood coagulation is factor VIII and said receptor binding competitor is a mixture of aprotinin and tPA.

5. (amended) A preparation according to claim 1, characterized in that said pro-protein of blood coagulation is vWF and said receptor binding competitor is a mixture of aprotinin and tPA.

Q2

7. (amended) A method of treating a patient suffering from phenotypic coagulation factor deficiency, comprising the step of administering a composition according to claim 1 to said patient.

8. (amended) The method according to claim 7, further comprising the step of selecting a patient who is vWF deficient.

Please cancel claim 9 without prejudice or disclaimer of the subject matter contained therein.

10. (amended) The method of claim 7, wherein said receptor binding competitor is a mixture of aprotinin and tPA.

11.(amended) The method of claim 7, wherein said pro-protein is blood coagulation factor VIII.

Please cancel claim 12 without prejudice or disclaimer of the subject matter contained therein.

CONCLUSION

In view of the foregoing, Applicants believe that all claims now pending in this application are in condition for examination. If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned attorney at (949) 250-6828.

Respectfully Submitted,

Janice Guthrie
Registration No. 35,170

Baxter Healthcare Corporation
PO Box 15210
Irvine, Ca 92623-5210
Telephone: (949) 250-6828
Facsimile: (949) 474-6330